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Abstract
Haptocorrin (HC) is a circulating corrinoid binding protein with unclear function. In contrast to transcobalamin, the other
transport protein in blood, HC is heavily glycosylated and binds a variety of cobalamin (Cbl) analogues. HC is present not
only in blood but also in various secretions like milk, tears and saliva. No recombinant form of HC has been described so far.
We report the expression of recombinant human HC (rhHC) in human embryonic kidney cells. We purified the protein with a
yield of 6 mg (90 nmol) per litre of cell culture supernatant. The isolated rhHC behaved as native HC concerning its spectral
properties and ability to recognize both Cbl and its baseless analogue cobinamide. Similar to native HC isolated from blood,
rhHC bound to the asialoglycoprotein receptor only after removal of terminal sialic acid residues by treatment with
neuraminidase. Interestingly, rhHC, that compared to native HC contains four excessive amino acids (…LVPR) at the C-
terminus, showed subtle changes in the binding kinetics of Cbl, cobinamide and the fluorescent Cbl conjugate CBC. The
recombinant protein has properties very similar to native HC and although showing slightly different ligand binding
kinetics, rhHC is valuable for further biochemical and structural studies.
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Introduction
Vitamin B12 (cobalamin, Cbl) is a water soluble vitamin which
is involved in biosynthetic processes in every living cell. Its
transport within the human body is mediated by an elaborate
system involving three soluble binding proteins, haptocorrin (HC)
(previously referred to as transcobalamin I or R-binder), intrinsic
factor (IF) and transcobalamin (TC) as well as their receptors [1].
IF ensures the uptake of Cbl in the intestinal cell, and once Cbl
is transferred to the blood, TC is needed in order to transport Cbl
into all cells of the body. The role for HC is only partially known
[2]. In the upper digestive tract, salivary HC captures dietary Cbl
and mediates its transport through the stomach. Subsequently, HC
is degraded by pancreatic enzymes in the duodenum, whereupon
the released Cbl binds to IF and is transferred to the blood. In the
blood, approximately 75% of all Cbl is bound to HC whereas the
remaining fraction is bound to TC [3]. Interestingly, HC binds not
only Cbl but also so-called Cbl analogues, which are corrinoids
without cofactor activity in mammalian cells. Up to 40% of all
corrinoids bound to HC in plasma are Cbl analogues [2,4,5].
While the presence of IF and TC is restricted to a few
compartments in the body, HC is present in both the circulation
and in most exocrine secretions like saliva, tears, and human milk
[2].
In contrast to TC, HC is heavily glycosylated and has an
apparent molecular mass of 60–70 kDa of which approximately
25% are attributed to glycans. Depending on the source of
synthesis, different glycoforms of HC have been described [6]. HC
that lacks terminal sialic acid is known to be rapidly cleared by the
asialoglycoprotein receptor in the liver [7], while for sialylated
HC, no receptor has been identified.
Interestingly, some tumour types, including fibrolamellar
hepatocellular carcinoma, have been described to express high
amounts of HC [8,9]. In recent studies, this protein has been
proposed as a diagnostic marker in breast cancer [10,11] and
fibrolamellar hepatocellular carcinoma [8]. Expression of HC in
cancer can reach high levels, and HC has very recently even been
proposed as a target molecule for cancer diagnosis or therapy
[11,12].
Both IF and TC have been expressed in various hosts like
plants, yeast, and insect cells [13,14,15,16], and their structures in
complex with Cbl have been solved by X-ray crystallography
[17,18]
The overall structure of both proteins is similar and consists of
an N-terminal a-domain and a C-terminal b-domain connected
by a flexible linker. In contrast to IF and TC, neither expression of
recombinant HC nor its crystallisation have been reported so far.
Thus, the only source of HC for biochemical studies is purified
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consuming experiments, e.g. crystallographic analysis.
The present work reports expression, purification and char-
acterisation of recombinant human HC (rhHC) in the cell line
HEK293. The C-terminal Myc-His-tag was removed using a
thrombin-cleavage site, and the protein was further purified to
.98% purity. We compare the biochemical properties of rhHC to
native human HC isolated from plasma of a cancer patient [19].
Results
Purification of rhHC from HEK293 culture supernatant
We developed a mammalian cell expression system for
production of rhHC, which contained a thrombin-cleavable, C-
terminal fusion tag consisting of the Myc and pohlyhistidine
peptides (Myc-His-tag) for affinity purification and immunological
detection by anti-Myc-tag antibody (Figure 1A). The expressed
fusion protein was purified by His-tag Ni
2+ affinity and size
exclusion chromatography. Tagged protein was obtained at high
yields (10 mg/L culture supernatant) and relatively high purity
(Figure 1B, lanes 3 and 4). Subsequently, the fusion tag was
removed from rhHC by cleavage with thrombin and rhHC was
further purified by a Ni
2+ affinity chromatography step to remove
uncleaved rhHC, the cleaved tag peptides and any protein
impurities with affinity for Ni
2+ (Figure 1B, lane 5). A final size
exclusion chromatography step was performed to remove throm-
bin (Figure 1B, lane 6). Western blotting of the tagged and
untagged products indicated complete removal of the fusion tag
after thrombin cleavage (Figure 1C).
Comparison of the two size exclusion chromatograms showed
that the tagged intermediate product was eluted as a main rhHC
peak with a shoulder and some impurities (Figure 1D), whereas
only a single peak was observed in the final untagged rhHC
preparation (Figure 1E).
The purified rhHC appeared as one single but broad band on
SDS/PAGE after Coomassie staining (purity .98%), and the
yield of rhHC was estimated as 6 mg (90 nmol/L) from one litre of
cell culture supernatant. N-terminal sequencing (EICEVS…)
confirmed the identity and correct maturation of the purified
protein. At the C-terminus, four excessive amino acid residues
(…LVPR) remained after cleavage with thrombin. The apparent
molecular weight of rhHC on SDS/PAGE was comparable to the
weight of native HC purified from plasma of a patient
hepatocellular carcinoma [20] (Figure 1B and C, lane 7).
Glycosylation pattern of rhHC
The molecular weight of the purified rhHC was approximately
60 kDa as determined by 10% SDS/PAGE gel stained by
Coomassie Brilliant Blue (Figure 2A lane 2) and Western blotting
(Figure 2B, lane 1 and 2). This is significantly higher than the
theoretical value of the protein backbone of 46 kDa. In agreement
with SDS/PAGE, MALDI-MS analysis also revealed a molecular
mass of rhHC of approximately 65 kDa (Fig. 2C). The broad peak
of mass distribution is expected due to heterogeneous glycosylation
patterns of rhHC.
To further analyse the extent of glycosylation, several
deglycosylation procedures were used. Incubation with PNGase
F alone did not remove N-glycans completely (Figure 2A, lane 5
and 10). Simultaneous treatment of rhHC with neuraminidase and
PNGase F resulted in a lower molecular weight of the protein,
indicating a high content of terminal sialic acids (Figure 2A, lane 4
and 9). For complete deglycosylation with PNGase F, a
denaturation step prior to deglycosylation is needed in order to
decrease the protein mass to the expected value of about 46 kDa
(Figure 2A, lane 3). MALDI-MS analysis of the denatured and
deglycosylated protein showed two peaks: one with the expected
mass of the protein backbone 46058.6 Da which was close to the
theoretical value of 46076.1 Da for rhHC (NCBI Reference
Sequence: NP_001053) including the mass of the four excessive
residues present (…LVPR), reduced S-S bonds and assuming eight
converted Asn to Asp residues by action of PNGase F [21]. The
second peak had a noticeably higher mass of 47054.4 Da
(Figure 2D). This strongly indicates remaining posttranslational
modification on rhHC even after removal of N-linked glycans.
Periodic acid-Schiff (PAS) staining supports this finding, as a
residual amount of carbohydrates can still be detected after the
deglycosylation procedure (Figure 2A, lane 8).
All together our results indicate that carbohydrates contribute
with approximately 20 kDa to the total mass of rhHC.
There are nine sites for N-linked glycosylation showing the
consensus sequence Asn-X-Thr/Ser. Database research and
previous published studies [22,23] predict only eight of them to
be glycosylated. In contrast to IF with glycosylation only at its C-
terminus, the predicted glycosylation sites of HC are situated on
both the a- and b-subunit as well as the N-terminal part of the
linker region [23].
We analysed the sequence for putative O-glycosylation sites
using NetOGlyc 3.1 [24]. Two potential sites for mucin-type O-
linked glycosylation were identified on Thr301 and Thr303, which
are located on the linker region between the a- and b-subunit of
HC. Analysis of the sequences of 25 orthologues (ExPasy) revealed
putative O-glycosylation sites in the linker region in 21 of 25 HC-
like-sequences (Table S1). Thus, O-glycosylation of the linker may
be a common feature of HC-like proteins in various species.
Absorbance spectra of rhHC
Absorbance spectrum of rhHC in complex with aquo-Cbl is
presented in Figure 3A and shows characteristics similar to those
previously reported for native human HC (Table 1). Adding azide
caused a remarkable shift in the absorption maximum of the
gamma peak, which is also characteristic of native human HC
[25,26]. This change is caused by attachment of azide-anion to the
‘‘upper surface’’ of Cbl accompanied by rearrangements in the
binding site of HC [26].
The spectral features of the complex rhHCNaquo-Cbl were
explored further when rhHC was saturated with aquo-Cbl added
in steps at concentrations below the total binding capacity of the
protein (Figure 3B). This allowed calculation of the molar
absorbance coefficients of aquo-Cbl when bound to rhHC
(Table 1). These parameters helped to evaluate the active protein
fraction (AP) as previously shown for IF [27]. For rhHC the value
of AP was found from the ratio of R=A280/A356 according to the
equation below and the values of absorbance coefficients from
Table 1.
AP~
52200{R:100
R:26100{23100
All examined samples of rhHC showed an AP$0.95 (i.e. $95%
of the protein bound Cbl stronger than adsorbent of aquo-Cbl, see
methods). The best measured values were R=2.89 and AP=0.99
indicate an excellent binding activity. In contrast to previously
reported purification methods [28,29,30], rhHC was produced
and isolated directly in the unsaturated (apo-) form without
exposure to Cbl-containing adsorbents and denaturing agents.
Expression of Haptocorrin in Mammalian Cell
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quality, resulting in a high AP-value. Nevertheless, the effect of
GdnHCl treatment was examined on a preparation with
AP=0.95. rhHC was saturated with Cbl and then subjected to
dialysis against GdnHCl, see ref. [31] for details. No decrease in
the binding activity was found after renaturing of apo-rhHC
(AP=0.95).
Binding of Cbl and cobinamide to rhHC
The most prominent characteristic of HC is its ability to bind
not only Cbl but also Cbl analogues, for example the baseless
corrinoid cobinamide (Cbi). We analysed the ability of Cbl and
Cbi to compete with labelled
57Co-Cbl for the binding to rhHC.
Comparable binding curves for rhHC and native HC (Figure 4)
point to preservation of this characteristic in rhHC. It should be
mentioned, that half-inhibition concentrations, IC50, cannot be
connected directly to the dissociation constants (see below). For
Cbi this is because equilibration of the mixture of labeled Cbl +
Cbi + HC may require several days of incubation.
Binding and dissociation kinetics of the fluorescent Cbl-
conjugate CBC, Cbl and Cbi
A more detailed examination of the binding kinetics was
performed in a competitive assay, where the fluorescent ligand
CBC [32] alone or in the mixture with a test ligand (Cbl or Cbi)
reacted with rhHC over time. Attachment of CBC to Cbl-binding
proteins causes increase in the quantum yield of the fluorophore,
which facilitates monitoring of the protein - CBC interactions
[32,33]. Presence of a non-fluorescent ligand X decreases the
signal, because the binding goes along two competing routes
HCNCBC r HC R HC?X (reactions behave as irreversible
processes within 0.2 s). The records for interaction between rhHC
and either CBC alone or CBC+ Cbl/Cbi mixtures are shown in
Figure 5A. The binding and dissociation rate constants k+s and
k2s, as well as the equilibrium dissociation constant KD were
calculated for all ligands by computer fitting as explained
elsewhere [33] and the results are listed in Table 2. Compared
to previously reported values for native HC, all current binding
rate constants (k+s) were 2–3 fold lower. This difference could not
be explained by possible concentration error (610%, examined by
Figure 1. Purification of rhHC. rhHC purified from approximately 0.5 L HEK293 cell culture supernatant. (A) Sequence alignment of native HC and
tagged rhHC. Thrombin cleavage site (bold), Myc-tag (underlined) and 66His-tag (italic) (B) Coomassie stained SDS/PAGE and (C) Western blot
analysis of the different purification steps. Lanes: 1, standards, 2, supernatant of HEK293 cells transfected with rhHC, 3, elution of first Ni
2+ affinity
chromatography (tagged rhHC), 4, peak fraction of first size exclusion chromatography (tagged rhHC), 5, flow-through of second Ni
2+ affinity
chromatography after thrombin cleavage, 6, peak fraction of second size exclusion chromatography, 7, human native HC [9]. (D) and (E) UV-
chromatograms at 280 nm of first and second size exclusion chromatography before and after thrombin cleavage on a Superdex 200 column at a
flow rate of 48 ml h
21. Elution volumes of Blue Dextran 2000 (V0) and albumin (Valb, 67 kDa) are marked with arrows.
doi:10.1371/journal.pone.0037421.g001
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the concurrent tests with two other proteins (TC and IF) revealed
the expected values of k+s=60–70 ? 10
6 M
21 s
21 for both CBC
and Cbl [26], not shown.
The dissociation kinetics was examined in chase experiments
which obeyed (within the examined time scale) one of the below
schemes: HC?CBC R HC R HC?Xo rH C ?X R HC R
HC?CBC (first step was rate limiting). The dissociation kinetics of
the ligands CBC, Cbl and Cbi was measured after formation of the
corresponding complexes with rhHC, followed by addition of
external CBC (or Cbl in the case of CBC itself) (Figure 5B). The
dissociation rate constants were then calculated from linear slopes
(Table 2). In several cases a small ‘‘jump’’ in the dissociation was
observed at the beginning of the reaction (e.g. dissociation curves
for Cbl and Cbi, 0–1000 s interval). This fast exponential increase
(0.5–3% of the total amplitude) was ascribed to presence of a small
fraction of partially denatured protein, where the exchange of
ligands was facilitated. This part of the curve was ignored, and
only the following linear component was used to calculate the
dissociation velocity of the ligand (v2=k2s ? [rhHCNS]). It should
be understood, that evaluation of rate constants below 3 ?
10
26 s
21 within the examined time scale cannot be precise, and
that the records were used for comparison of different ligands
rather than for precise quantification of k2s.
The rates of CBC and Cbl dissociation from rhHC (k2s#3 ?
10
26 s
21) were apparently similar to each other and to the
constants reported for native HC (k2s=5 ? 10
27 s
21) measured
more accurately over a period of 100 h [33]. On the other hand,
Figure 2. Glycosylation pattern of rhHC. PAS staining revealed heavy glycosylation of rhHC. (A) Coomassie (lane 1–5)/PAS (lanes 6–10) staining
of proteins separated on 10% SDS/PAGE. Lanes: 1/6, standards, 2/7, rhHC, 3/8, denatured and deglycosylated (PNGase F) rhHC, 4/9, rhHC overnight
incubated with PNGase F and neuraminidase, 5/10, rhHC overnight incubated with PNGase F. (B) Western blot analysis of tagged rhHC using anti-
Myc-tag antibody. Lane 1: denatured rhHC, lane 2: rhHC, lane 3: denatured and deglycosylated rhHC. (C) MALDI-MS analysis of rhHC. (D) MALDI-MS
analysis of the denatured and deglycosylated (PNGase F) rhHC.
doi:10.1371/journal.pone.0037421.g002
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(k2Cbi<2 ? 10
25 s
21). An earlier study demonstrated nearly equal
dissociation velocities for native HC and a group of corrinoids
including Cbl and Cbi (k2s=5 ? 10
27 s
21) [33]. Three prepara-
tions of rhHC (one after GdnHCl refolding) were examined and
none of them showed dissociation of Cbi comparable to that of
Cbl or CBC (Figure 5B). Repeated records for the same
preparation did not reveal much variation (not shown). Though
the overall affinity of rhHC for Cbi was formidable (Kd,Cbi<1 pM),
it was noticeably lower than that of native HC (Kd,Cbi=7 fM). It
seems that adjustment of Cbi in the binding site of rhHC is not
completely normal. Considering the two other ligands (Cbl and
CBC), difference between rhHC and native HC was less obvious
and concerned mostly k+s.
Interaction of rhHC with the asialoglycoprotein receptor
Depending on the source of expression, different isoforms of HC
exist in human blood and extracellular fluids [19]. Notably,
different half-lives are associated with these isoforms, probably
caused by fast clearance of HC-isoforms with low sialic acid
content by the asialoglycoprotein receptor [7]. We tested whether
125I-labelled rhHC would be readily taken up by HepG2 cells
expressing the asialoglycoprotein receptor involved in HC
clearance [34]. As with native HC, rhHC was not internalised
over the measured time span of 6 h (Figure 6B). Only after
removal of terminal sialic acid by neuraminidase, rhHC and
native HC were internalised. Removal of the terminal sialic acid
residues was qualitatively determined by SDS/PAGE (Figure 6A).
The cellular uptake did not depend on the saturation of the
protein with Cbl (Data not shown).
Discussion
We here report the first successful expression system for
recombinant HC. Unlike the expression systems used for
production of IF and TC, mammalian cells, such as human
embryonic kidney cells, are able to glycosylate proteins in patterns
characteristic of higher eukaryotes, yielding products that are
expected to be highly similar to their natural human counterparts
[35].
In comparison to other sources of human HC such as saliva
(15–72 nmol/L), plasma (0.25–84 nmol/L) or milk (4.5–
180 nmol/L) [2], the obtained quantity of recombinant protein
(90 nmol/L) is comparable or substantially higher. The protein
demonstrated a high Cbl binding capacity of 95–99%, and its
glycosylation pattern indicated the presence of N- and O-
glycosylations. Unlike HC present in saliva and granulocytes
rhHC was highly sialylated. Interaction with asialoglycoprotein
receptor took only place after removal of terminal sialic acids. We
therefore concluded that rhHC represents an isoform that is
comparable to HC present in human serum.
We demonstrated the recombinant protein’s ability to bind Cbl
as well as its baseless analogue Cbi. Furthermore the absorbance
spectrum of rhHC showed close similarity to the spectrum of
Figure 3. Absorbance spectra of rhHC-Cbl complexes. The absorbance spectrum of Cbl bound to rhHC exhibited a normal transition pattern.
(A) Spectrum of rhHC (13.8 mM) in either apo-form or saturated with aquo-Cbl (excess removed) with or without sodium azide (2 mM), pH 7.5, 22uC.
(B) Spectra of aquo-Cbl (4.48 mM) added stepwise to rhHC (26.3 mM), dilution was corrected, pH 7.5, 22uC. The data were used for calculation of the
coefficients of molar absorbance, see main text and Table 1.
doi:10.1371/journal.pone.0037421.g003
Table 1. Coefficients of molar absorbance of rhHC (free or in complex with aquo-Cbl, pH 7.5).
Protein species, e 280 nm c, 356 nm D, 415 nm b, 509 nm a, 529 nm
rhApoHC, e0 52?200
a) 1 0 0 2 02 02 0
rhApoHC + aquo-Cbl,
+De
+23?100 +26?100 5?480 9?930 10?030
rhHoloHC, e 75?900 26?200 5?500 9?950 10?050
Native HoloHC, e n.d. 28?600
b) 5?400
b) 10?300
b) 10?400
b)
a)Calculated from the composition of the mature protein, e280=5500NNTrp +1490NNTyr +125NNS-S ,M
21cm
21 [42].
b)From Reference [31].
n.d. not determined.
doi:10.1371/journal.pone.0037421.t001
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testifies that the organization of the Cbl binding site in rhHC is
comparable to that of native HC.
At the same time, the binding rate constants of all ligands were
lower than those of native HC. Dissociation velocity of the
examined analogue Cbi was also higher than expected. These
subtle differences of rhHC compared to native HC were explained
by presence of a peptide elongation attached to Tyr410 involved in
the interaction with Cbl.
The finally isolated form of rhHC had four excessive residues
(…LVPR) remaining at the C-terminal end discriminating it
structurally from native HC. We conjecture that attachment of the
excessive peptide (…LVPR) to the C-terminal residue might affect
to some degree the binding of ligands resulting in lower affinity.
This peptide is directly conjugated to Tyr410 which is possibly
involved in the binding of Cbl according to the 3D model of HC-
Cbl complex deduced from the crystallographic studies of TC and
IF [23]. Such a disturbance might negatively affect the overall
affinity Kd and the binding rate constant k+s, because the C-
terminal b-domain is suggested to be the primary binding site of all
corrinoids [27,36]. Reduction in affinity was particularly visible for
the analogue Cbi, whose binding probably requires more
structural accuracy of the protein.
Figure 4. Interaction of rhHC with labelled Cbl in competition
with Cbl or Cbi. rhHC and native HC showed a very similar binding
behaviour towards Cbl and Cbi. rhHC and native HC were incubated
with increasing concentrations of unlabeled Cbl or Cbi (competitor) and
the amount of labelled Cbl bound to the proteins was recorded in % of
the amount of labelled Cbl bound without the presence of competitor.
doi:10.1371/journal.pone.0037421.g004
Figure 5. Binding and dissociation kinetics of the fluorescent conjugate CBC and Cbi. Kinetic measurements revealed a subtle difference
between rhHC and native HC. (A) Binding kinetics. rhHC was mixed with either CBC or CBC + Cbl/Cbi (all 0.5 mM), pH 7.5, 22uC. Appearance of
rhHC?CBC complex was monitored over time according to increasing fluorescence normalized to the maximal amplitude of the signal. The binding
rate constants were calculated by computer fitting (solid lines). (B) Dissociation kinetics. rhHC was mixed with either CBC or the non-fluorescent test
ligands Cbl and Cbi (all 1 mM, pH 7.5, 22uC, 2 min incubation), whereupon either Cbl (1 mM) or CBC (1 mM) was added. Change in the concentration of
rhHC?CBC complex was monitored over time according to the normalized fluorescent response. Dissociation of Cbi was tested in three different
preparations of rhHC (all three curves are presented, see also Table 2). Best fits are shown by solid lines. The dissociation rate constants were
calculated from the linear slopes of the produced charts (examples indicated by dashed lines). Alternative linear slopes are shown for rhHC?Cbl
dissociation.
doi:10.1371/journal.pone.0037421.g005
Table 2. Binding and dissociation rate constants (k+/2CBC, k+/
2Cbl, k+/2Cbi) and equilibrium dissociation constants (Kd)a t
20uC and pH 7.5.
k+s k2s Kd
(M
21s
21)( s
21)( M )
rhHC
CBC 62/64/56
b) ? 10
6 <0.5/2/1
b) ? 10
26 <20 ? 10
215
Cbl X/19/X? 10
6 X/#3/X? 10
26 #100 ? 10
215
Cbi 33/21/X
b) ? 10
6 1.4/2.2/2.1
b) ? 10
25 1000 ? 10
215
Native HC
a)
CBC 124 ? 10
6 <5 ? 10
27 (<4 ? 10
215)
Cbl 90 ? 10
6 <5 ? 10
27 (<6 ? 10
215)
Cbi 73 ? 10
6 <5 ? 10
27 <7 ? 10
215
a)From Reference [33].
b)Measurements on different rhHC preparations with the active protein
fractions of 0.99/0.95/0.95 (the last sample was obtained after GdnHCl refolding
of rhHC). If no measurement was conducted, the result is notated as X.
doi:10.1371/journal.pone.0037421.t002
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and the expression system provides us with the possibility to
produce the protein in a sufficient amount for further biochemical
and structural studies.
Materials and Methods
Materials
Most reagents including salts and buffer components were
analytical grade and obtained from Sigma (Sigma-Aldrich
Logistics GmbH, Buchs, Switzerland), unless stated otherwise.
Ni-NTA Agarose was purchased from Qiagen (Hombrechtikon,
Switzerland). Restriction endonucleases, DNA ligase and Pfu DNA
Polymerase were obtained from Fermentas (Thermo Fischer,
Lausanne Switzerland) For comparative studies we used native
human HC present in saliva for binding studies [37] or purified to
homogeneity from human plasma as previously described [30] for
studies on the purified protein. Saliva was collected as part of a
previously published research project on HC in saliva [38] and as
stated in the paper all of the individuals gave informed consent.
Plasma was obtained from a patient with hepatocellular carcinoma
as left-overs from routine testing [9].
Cell Culture
HEK293 cells (DSMZ-Deutsche Sammlung von Mikroorganis-
men und Zellkulturen GmbH, Braunschweig, Germany) were
grown in Dulbecco’s modified Eagle’s medium containing 4.5 g/L
glucose, supplemented with 10% fetal calf serum, 100 U/mL
penicillin, 100 mg/mL streptomycin, 0.25 mg/mL fungizone, and
2 mM glutamine in a 5% CO2 incubator at 37uC. HepG2 cells
(Institut fu ¨r angewandte Zellkultur, Dr. Toni Lindl GmbH,
Munich, Germany) were grown in minimum essential medium
with Earl’s basal salts supplemented with 10% fetal calf serum,
100 U/mL penicillin, 100 mg/mL streptomycin, 0.25 mg/mL
fungizone, 2 mM glutamine, 1% non-essential amino acids, and
1 mM sodium pyruvate. All tissue culture reagents were purchased
from BioConcept (Basel, Switzerland).
Plasmid Construction
The cDNA for human HC (pCMV6-TCNI RC222285, Myc-
DDK-tagged ORF clone of Homo sapiens transcobalamin I
(TCN1) NCBI Reference Sequence: NM_001062.2, as transfec-
tion-ready DNA) purchased by Origene (Lab Force, Nunningen,
Switzerland) was cloned into the EcoRI/XhoI site of pcDNA4/
myc-His A vector (Invitrogen AG, Basel) by standard molecular
biological techniques. A thrombin cleavage recognition site
(LeuValProArgQGlySer) was positioned at the fusion junction
to release the HC protein from its tag. The primers (Microsynth
AG, Balgach, Switzerland) used were 59-TAATACGACTCAC-
TATAGGG-39 and 59-CCGCTCGAG AGATCCACGCG-
GAACCAGGTATTTGCTCCAGCGAACC-39. All selected
clones were verified by DNA sequencing (Microsynth AG,
Balgach, Switzerland).
Expression of rhHC
Cells were transfected using Lipofectamine 2000 (Invitrogen
AG, Basel) following the manufacturer’s instructions. After 72 h,
the cells were detached with phosphate-buffered saline (PBS)/
1 mM EDTA and replated onto 10 new 10 mm cell culture dishes
in complete medium supplemented with 400 mg/mL Zeocin
TM
selection reagent (Invitrogen AG, Basel, Switzerland) and 20 mM
HEPES, which was changed every 4–5 days. After about 3 weeks,
resistant colonies were isolated and grown as described elsewhere
[39].
Purification of rhHC and thrombin treatment
High producer transfectomas were stimulated with 6 mM
sodium butyrate in growth medium (without Zeocin and HEPES)
for 8 days. The cell culture medium was centrifuged for 30 min at
7000 g, 4uC, clarified by filtration through a 0.2 mM Express plus
filter (Millipore AG, Zug, Switzerland) and concentrated using an
Amicon Filter device (MWCO 10000, Millipore AG). After adding
300 mM NaCl and 5 mM imidazol to the obtained solution
(0.2 L) it was applied to a Ni
2+ affinity column. Absorption of
rhHC was carried out at room temperature with gravity flow. The
resin was washed with 6 volumes of PBS, 6 volumes of PBS/1 M
NaCl and 6 volumes of PBS/0.5 M NaCl/20 mM imidazole.
Bound proteins were eluted in 1 mL fractions with PBS/300 mM
imidazole. Fractions were analysed by SDS/PAGE, and the peak
fractions were polished using HILoad
TM 16/60 Superdex 200 gel
filtration column and A ¨kta
TMprime system (Amersham Bioscienc-
es). Gel filtration was conducted at room temperature at a flow
rate of 48 mL h
21 using PBS.
The peak fractions were then dialyzed against thrombin
cleavage buffer (20 mM Tris-HCl pH 8, 150 mM NaCl,
2.5 mM CaCl2) and incubated for 72 h at room temperature
with thrombin (from human plasma, Sigma) (5 U/mg protein) on
an orbital shaker. The Myc/His-tag was then removed by using a
Ni
2+ affinity column (2.5 mL) with gravity flow and the flow
through was collected in 1 mL fractions using PBS. The rhHC-
containing fractions were then subjected again to gel filtration as
Figure 6. Internalisation of
125I-rhHC into HepG2 cells.
Comparison of rhHC and human native HC with or without pre-
treatment with neuraminidase in order to remove terminal sialic acid.
(A) SDS/PAGE analysis after treatment with neuraminidase. (B)
Internalisation of
125I labelled proteins after 0, 1.5, 3 and 6 h incubation
time. Standards are indicated with M.
doi:10.1371/journal.pone.0037421.g006
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were pooled and concentrated to 1–2 mL by ultrafiltration on an
Amicon filter (MWCO 30000, Millipore AG). The protein was
stored frozen at 220uC.
Edman degradation
The Edman degradation was performed at the Functional
Genomics Center Zu ¨rich, Switzerland.
5 ml of the sample was diluted with 100 ml 0.1% trifluoroacetic
acid (TFA) and loaded on a PVDF membrane (ProSorb, Applied
Biosystems). The membrane was washed with 100 ml 0.1% TFA
and dried. Edman degradation was performed on a Procise 492
cLC (Applied Biosystems) according to the manufacturer’s
instructions.
Deglycosylation of rhHC
rhHC was denatured for 5 min at 95uC in denaturation buffer
(100 mM, pH 8 Na-phosphate, 25 mM EDTA, 0.5% (w/v)
Triton X-100, 0.2% (w/v) SDS, 1% (v/v) b-mercaptoethanol),
cooled down and deglycosylated using the enzymes PNGase F
(Roche diagnostics GmbH, Rotkreuz, Switzerland) and neuramin-
idase (Sigma-Aldrich, Switzerland) according to Morkbak et al.
[40].
SDS/PAGE and Western blot analysis
Proteins were separated by SDS/PAGE under reducing
conditions and were transferred to PVDF (polyvinylidene
difluoride) membranes (Millipore AG, Switzerland) with a semi-
dry blotting device (Bio-Rad Laboratories AG, Reinach, Switzer-
land). Incubations with anti-Myc-tag mouse mAb (9B11) (Cell
Signaling Technology, BioConcept, Basel, Switzerland) or Trans-
cobalamin I (M-16) (Santa Cruz Biotechnology, Lab Force,
Nunningen, Switzerland) were according to the manufacturer’s
protocol overnight at 4uC in TBST (20 mM Tris HCl pH 7.5,
500 mM NaCl, 0.05% Tween 20) containing 2% BSA. Detection
was done with secondary horseradish peroxidase (HRP)-linked
antibodies from Cell Signaling Technology and Santa Cruz
Biotechnology, Inc. and the enhanced chemiluminescence (ECL)
western blotting substrate from Pierce (Perbio Science Switzerland
S.A., Lausanne, Switzerland).
Mass spectrometric analysis
The MALDI-MS analyses were performed at the Functional
Genomics Center Zu ¨rich, Switzerland. The denatured and
deglycosylated sample was first precipitated by Trichloroethane
(TCA). The dried pellet or 1 ml of the untreated sample was
dissolved in 5 ml hexafluoro-2-propanol (HFIP) diluted 1:10 in
matrix (saturated sinapinic acid (CHCA) in 0.1% trifluoroacetic
acid (TFA) and 50% acetonitrile) and then spotted on the target.
In order to get rid of salts, buffer and anorganic impurities, the dry
crystals were then washed with 0.1% TFA solution and air dried.
The samples were then analysed by MALDI-MS on a Bruker
Autoflex II mass spectrometer equipped by a 337 nm Nitrogen
laser.
Spectral studies
Absorbance spectra were recorded on Varian Cary 50
spectrophotometer (Varian, Australia) at 5–15 mM concentrations
of Cbl and rhHC dissolved in 0.2 M Na-phosphate buffer, pH 7.5,
22uC.
Prior to AP measurements, rhHC was saturated with an excess
of aquo-Cbl, free aquo-Cbl was bound to the specific tetrazole
adsorbent [41], whereupon the spectrum of rhHC?Cbl was
recorded and compared to the control sample (buffer + aquo-
Cbl + adsorbent). After subtraction of the control spectrum, the
absorbance ratio and AP were calculated.
Binding of Cbl and Cbi to rhHC
The ability of rhHC to bind Cbl (Sigma-Aldrich, Denmark) and
Cbi (Sigma-Aldrich, Denmark) was explored using a competitive
assay previously described [37]. In brief, rhHC or partly purified
native apoHC was incubated with
57Co-Cbl (Kem-En-Tec,
Taastrup, Denmark) together with increasing amounts of Cbl or
Cbi overnight. Unbound
57Co-Cbl was removed by charcoal
precipitation and bound
57Co-Cbl was measured employing a
Wizard Automatic Gamma Counter (Perkin Elmer).
Refolding of rhHC
rhHC (10 mM) was saturated with an excess of CNCbl (20 mM)
and subjected to dialysis against a 50-fold volume excess of 5 M
GdnHCl (30uC, 180 rpm). The solution was changed at days 2
and 3. Incubation was stopped after day 4, whereupon rhHC was
renatured by dialysis against 0.2 M Na-phosphate buffer pH 7.5,
see also ref. [31].
Binding studies with fluorescent Cbl-conjugate CBC
All reactions were performed in 0.2 M Na-phosphate buffer,
pH 7.5, 22uC. The binding kinetics was monitored by means of
stopped flow method (DX.17 MV stopped-flow spectro-fluorom-
eter, Applied Biophysics, UK) using the fluorescent response from
a Cbl-conjugate CBC [32,33], excitation 525 nm, emission
.550 nm, slit 1.5 mm, voltage 390, bandpass of 18.6 nm, light
path of 1 cm. The binding reaction was started after mixing of
rhHC either with CBC alone or CBC + corrinoid. The final
concentrations of all reacting species were 0.5 mM. The maximal
amplitude of the fluorescent response in the mixture rhHC + CBC
corresponded to 0.5 mM of rhHCNCBC complex. Competition
between CBC and a non-fluorescent ligand for the binding to
rhHC decreases the amplitude. The relevant rate constants of
association were calculated by computer fitting, as described
elsewhere [32,33].
The dissociation reactions were monitored on fluorometer
Varian Eclipse (Varian, Australia) using the fluorescent response of
CBC, excitation 525 nm (slit 5 nm), emission 550 nm (slit 5 nm),
photomultiplier 600 V. In one setup the pre-formed rhHC?CBC
complex (1 mM, 2 min) was mixed with free Cbl (1 mM), and
decrease in fluorescence was registered due to rhHC?CBC « Cbl
exchange. Dissociation of the non-fluorescent ligands (Cbl or Cbi)
was measured in similar chase experiments. The test ligand was
mixed with rhHC (1+1 mM, 2 min), whereupon 1 mMo f
exogenous CBC was added. The endogenous ligand dissociated
from the protein (rate limiting step), whereupon CBC immediately
bound to rhHC and increased fluorescence.
Internalisation studies
The proteins were labelled with
125I using the Iodogen method
(Pierce). Labelled protein was purified on a PD10 column (GE
healthcare, Glattbrugg, Switzerland). HEPG2 cells were incubated
in twelve-well plates in triplicates with about 1 mg of labelled
protein for 1 h at 4uC. The plates were then incubated for 0, 1.5,
3, 6 h at 37uC for internalisation. After these times, the cells were
washed twice with PBS/0.1% bovine serum albumin and then
incubated for 5 min with ice-cold acid wash buffer (50 mM
Glycine-HCl, 100 mM NaCl, pH 2.8) to remove the cell-surface
bound radioligand. Subsequently, cells were solubilised by
incubation with 1 N NaOH for 5 min. at 37uC. At each time
Expression of Haptocorrin in Mammalian Cell
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(cell-surface bound) and the solubilised cells (internalised) were
determined with a NaI-c-counter (Cobra II Packard, Canberra
Packard GmbH, Frankfurt, Germany).
Supporting Information
Table S1 Amino acid sequences of the linker region
connecting the alpha- and beta-domains of HC aligned
from different species. Putative N-glycosylation sites are
indicated in red. Putative O-glycosylation sites (predicted by
NetOGlyc 3.1) are indicated in bold letters.
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